Early phase drug development is often defined by speed, but planning is essential to avoid added costs and delays in the later stages of a molecule’s journey.
Detailing bioanalytical approaches to investigating antibody-drug conjugates (ADCs) along with recommendations for drug sponsors currently developing them.